BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The…
Industry Peers
Medical Instruments & Supplies| Headline | Source | Time |
|---|---|---|
Older | ||
 BioLife Solutions (BLFS) Is Up 7.2% After Swinging From Loss To Q2 Profit - What's Changed In the past quarter, BioLife Solutions, Inc. reported second‑quarter 2026 sales of US$28.47 million, up from US$23.44 million a year earlier, with net income improving to US$45.10 million from a net loss of US$15.84 million. This shift from loss to earnings, including basic earnings per share from continuing operations moving to US$0.92 from a loss of US$0.32, signals a significant change in the company’s recent operating performance. With this sharp move from loss to profit, we’ll examine... | ||
 BioLife Solutions, Inc. (BLFS) Q2 Earnings and Revenues Surpass Estimates BioLife Solutions (BLFS) delivered earnings and revenue surprises of +500.00% and +1.48%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Repligen (RGEN) Held An M&A Call With BioLife Solutions. Repligen (NasdaqGS:RGEN) and BioLife Solutions recently held a merger and acquisition call. The discussion focused on potential combinations or partnerships in bioprocessing and cell and gene therapy tools. The call represents new corporate activity that is separate from routine earnings updates. Repligen enters this M&A discussion with BioLife Solutions while its shares trade at $131.06. The stock is up 9.5% over the past year, although it is down 20.3% year to date and has declined 23.6%... | ||
 Repligen Reports Q2 Revenue Growth and Raises Full-Year 2026 Guidance Repligen Corporation (NASDAQ:RGEN) reported double-digit second-quarter revenue growth and increased its full-year 2026 financial guidance, citing strong order momentum and continued market outperformance while highlighting its pending acquisition of BioLife Solutions. Key Investor TakeawaysRepligen raised its full-year 2026 guidance following stronger first-half performance and continued order momentum. | ||
 Repligen to Expand Cell Therapy Capabilities With BioLife Buyout RGEN's $1.5 billion BioLife acquisition aims to expand its cell therapy capabilities, adding biopreservation products and expected revenue and EPS benefits. | ||
Sector Update: Healthcare Stocks Softer Late Afternoon Healthcare stocks declined late Wednesday afternoon, with the NYSE Healthcare Index down 0.4% and th | MMT Newswires | |
 Repligen to Buy BioLife Solutions for $1.5 Billion, Expanding Cell Therapy Reach Repligen (NASDAQ:RGEN) said it has signed a definitive agreement to acquire BioLife Solutions in a transaction valued at approximately $1.5 billion, adding a cell therapy-focused platform that management said will expand Repligen’s exposure to one of the faster-growing areas of bioprocessing. Presi | ||
Top Midday Stories: Trump Threatens Retaliation for Attacks in Strait of Hormuz; AMD to Supply MI450 GPUs to Anthropic The Dow Jones Industrial Average and the S&P 500 Index were up, while the Nasdaq Composite were down | MMT Newswires | |
IInsider Monkey | ||